Group 1: Company Overview and Product Information - The company has four production bases, with key products including Vitamin K3, chromium tanning agents, and various pharmaceutical raw materials [1] - The main applications of para-hydroxyphenol span multiple industries, including food, daily chemicals, pesticides, pharmaceuticals, dyes, and polymer materials [1] - The company has officially started selling para-hydroxyphenol in the PEEK field and is currently in the verification stage with major domestic PEEK manufacturers [2] Group 2: Regulatory Approvals and Product Registration - The company has obtained various regulatory approvals for iodine contrast agents, including registrations in China, India, Japan, and CEP certification [2] - Currently, the company holds registration certificates for two formulation products, with one product, Bisoprolol fumarate tablets, having commenced market promotion in 2024 [2] Group 3: Financial Performance and Inventory Management - The growth in performance for the first half of 2025 is attributed to the year-on-year price increase of certain vitamin products and a decrease in production costs [2] - The company maintains a large ending inventory balance due to its diverse product lines, which include vitamins, flavors, raw materials, and chromium salts, and is focused on improving asset turnover efficiency [2] Group 4: Supply Chain and Procurement - The company sources chromium ore locally in South Africa as needed and currently has no plans to acquire chromium mines [2] Group 5: Disclosure and Compliance - The investor relations activity did not involve any undisclosed significant information [2]

Core Viewpoint - Brother Technology Co., Ltd. is planning to issue A-shares to specific investors to raise funds primarily for expanding its production capacity of iodinated contrast agents, specifically increasing the production capacity of iodinated raw materials from 100 tons to 700 tons, with a total investment of approximately 69 million yuan for the project [1][9]. Group 1: Financial Overview - The company reported revenues of 3.41 billion yuan, 2.82 billion yuan, and a loss in 2023 due to declining prices of chromium salt products, which affected both revenue and gross margin [1][2]. - The gross margin for the main business was 24.83%, 10.40%, and 14.63% over the reporting periods, indicating significant fluctuations influenced by market conditions and raw material prices [4][5]. Group 2: Investment and Project Details - The funds raised will be allocated to construction, equipment purchase, and installation, leading to increased fixed asset depreciation and intangible asset amortization, which will raise operational costs [1][3]. - The project aims to achieve an annual production capacity of 600 tons of iodinated raw materials, with the feasibility of the project assessed based on market demand and competition [1][6]. Group 3: Risks and Challenges - There are risks associated with the inability to absorb the new production capacity if market demand does not meet expectations, potentially leading to excess capacity and increased competition [1][2]. - The company faces uncertainties regarding the economic benefits of previous fundraising projects, particularly if market conditions or regulatory environments change adversely [2][3]. - The company must navigate the complexities of regulatory approvals for its iodinated contrast agents, which could impact market entry and expected returns [5][6]. Group 4: Share Structure and Ownership - As of December 31, 2024, the company's total share capital is 106,370.05 million yuan, with 34.05% held as restricted shares and 65.95% as unrestricted shares [14]. - The top ten shareholders collectively hold 47.58% of the shares, indicating a diverse ownership structure [14].